BRPI0809386A2 - Modulação de micro ambiente de tumor - Google Patents

Modulação de micro ambiente de tumor Download PDF

Info

Publication number
BRPI0809386A2
BRPI0809386A2 BRPI0809386-5A BRPI0809386A BRPI0809386A2 BR PI0809386 A2 BRPI0809386 A2 BR PI0809386A2 BR PI0809386 A BRPI0809386 A BR PI0809386A BR PI0809386 A2 BRPI0809386 A2 BR PI0809386A2
Authority
BR
Brazil
Prior art keywords
cells
antibody
malignancy
interleukin
tumor
Prior art date
Application number
BRPI0809386-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Kandasamy Hariharan
Steffan Ho
Shabnam Tangri
Ted Yun
Arturo Molina
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0809386A2 publication Critical patent/BRPI0809386A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0809386-5A 2007-03-28 2008-03-28 Modulação de micro ambiente de tumor BRPI0809386A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90864507P 2007-03-28 2007-03-28
US60/908,645 2007-03-28
PCT/US2008/058744 WO2008119071A1 (en) 2007-03-28 2008-03-28 Modulation of tumor microenvironment

Publications (1)

Publication Number Publication Date
BRPI0809386A2 true BRPI0809386A2 (pt) 2014-09-09

Family

ID=39485176

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809386-5A BRPI0809386A2 (pt) 2007-03-28 2008-03-28 Modulação de micro ambiente de tumor

Country Status (8)

Country Link
US (1) US20100203010A1 (enExample)
EP (1) EP2139923A1 (enExample)
JP (1) JP2010522772A (enExample)
CN (1) CN101679522A (enExample)
AU (1) AU2008230724A1 (enExample)
BR (1) BRPI0809386A2 (enExample)
CA (1) CA2682027A1 (enExample)
WO (1) WO2008119071A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6014799B2 (ja) * 2010-07-20 2016-10-26 Ｌｉｎｆｏｐｓ有限会社 解析によるミクロな腫瘍免疫挙動の顕微鏡的把握方法
EP3147297B1 (en) * 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
US9907819B2 (en) 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015077532A1 (en) * 2013-11-21 2015-05-28 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3215163B1 (en) * 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
US20160206717A1 (en) * 2015-01-16 2016-07-21 Batu Biologics, Inc. Stimulation of immunity to endothelial cells, endothelial-like cells, and intratumor vascular channels derived from tumor tissue
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506915A (ja) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Also Published As

Publication number Publication date
JP2010522772A (ja) 2010-07-08
CA2682027A1 (en) 2008-10-02
WO2008119071A1 (en) 2008-10-02
CN101679522A (zh) 2010-03-24
US20100203010A1 (en) 2010-08-12
AU2008230724A1 (en) 2008-10-02
AU2008230724A8 (en) 2009-11-26
EP2139923A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
BRPI0809386A2 (pt) Modulação de micro ambiente de tumor
JP7021153B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
KR102233344B1 (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
KR102188001B1 (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
ES2384168T3 (es) Procedimientos de tratamiento usando anticuerpos CTLA-4
US20220273722A1 (en) Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
CN113474004A (zh) 用于治疗肿瘤的包含抗cd19抗体和自然杀伤细胞的药物组合
US8685640B2 (en) Medical methods and agents for use therein
JP2007530584A (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
US20100189716A1 (en) Treatment of hodgkins lymphoma
JP2022553643A (ja) 細胞傷害性ｔ細胞耐性腫瘍を治療するための組成物および方法
CN114729314A (zh) 用于癌症治疗的组合癌症疗法和细胞因子控制疗法
US11186634B2 (en) Antibodies targeting tumor associated macrophages and uses thereof
WO2019007075A1 (zh) 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
US20250375523A1 (en) Compositions and systems for combinatorial therapies containing fucosylated cells and immune checkpoint inhibitors and methods of production and use thereof
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
HK40109251A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
EP4568999A1 (en) Chimeric antigen receptor domains
Garris Contextualizing Anti-PD-1 Cancer Immunotherapy Treatment Through Visualization of Therapeutics in vivo
HK40014553A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
AU2014200678A1 (en) Antibodies to CD200 and uses thereof in inhibiting immune responses

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.